IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$74.48 USD
+0.12 (0.16%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $74.42 -0.06 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ITCI 74.48 +0.12(0.16%)
Will ITCI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ITCI
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
ITCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Misses Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for ITCI
Baird Q2 2024 Small/Mid Cap Growth Equity Fund Commentary
Intra-Cellular Therapies: A Buy Rating on Strong Commercial Performance and Robust Pipeline
Invesco Main Street Mid Cap Fund Q2 2024 Review
Intra-Cellular Therapies Moves Up In Market Cap Rank, Passing Caesars Entertainment
Executive reshuffles: Uranium Energy, Nutrien and Logitech International Companies in focus